Loading...
•
Dec 31, 2022
Tempest Q4 2022 Earnings Report
Reported financial results for the year ended December 31, 2022 and provided a corporate update.
Key Takeaways
Tempest Therapeutics reported a net loss of $35.7 million for the year ended December 31, 2022. The company ended the year with $31.2 million in cash and cash equivalents.
TPST-1120 randomized combination study in first-line HCC patients with partner Roche is fully enrolled, with initial data expected in the first half of 2023
New data on TPST-1120 biomarker and proprietary small molecule TREX1 inhibitor accepted for presentation at AACR 2023
TPST-1495 Phase 1 monotherapy and combination dose escalation and optimization ongoing, with initial data release planned by mid 2023
Ended the year with $31.2 million in cash and cash equivalents
Tempest
Tempest
Forward Guidance
Based on current cash position and operating plan, Tempest expects to have sufficient resources to fund operations through the second quarter of 2024.